Disseminated mycobacterial infections after tumor necrosis factor inhibitor use, revealing inborn errors of immunity

Int J Infect Dis. 2023 Jun:131:162-165. doi: 10.1016/j.ijid.2023.04.007. Epub 2023 Apr 8.

Abstract

Tumor necrosis factor-a inhibitors can be associated with increased risk of infections, particularly reactivation of latent tuberculosis or nontuberculous mycobacterium (NTM). However, because disseminated NTM is rare, inborn errors of immunity should be considered. We present three patients with disseminated NTM after tumor necrosis factor-a inhibitor use who were found to have inborn errors of immunity.

Keywords: Immunodeficiency; Inborn errors of immunity; Infliximab; Mycobacteria; TNF inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Mycobacterium Infections, Nontuberculous* / diagnosis
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Nontuberculous Mycobacteria
  • Tumor Necrosis Factor Inhibitors*
  • Tumor Necrosis Factor-alpha

Substances

  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha